South San Francisco, CA, Oct. 27, 2023– The California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, awarded $42.1 million to fund various translational research — from treating brain cancers and salivary gland conditions to advancing a therapy for a rare metabolic disease. The goal of CIRM’s Translational program is … Continue reading CIRM invests more than $42 million in translational-stage research

South San Francisco, CA – The California Institute for Regenerative Medicine (CIRM), the world’s largest institute dedicated to regenerative medicine, would like to congratulate Rocket Pharmaceuticals, Inc, a leading late-stage biotechnology company, on receiving U.S. FDA acceptance of the Biologics License Application (BLA) and Priority Review for RP-L201 (marnetegragene autotemcel), a lentiviral vector (LV)-based gene … Continue reading CIRM-Funded Program Targeting Rare Pediatric Disease Announces FDA Acceptance of Biologics License Application with Priority Review

The California Institute for Regenerative Medicine (CIRM) Alpha Clinics network specializes in delivering stem and gene cell clinical trials to patients. The key to the network’s success is the ability to foster partnerships with patients, medical providers, and clinical trial sponsors. The CIRM Alpha Clinics Network consists of nine leading medical centers throughout California.  Every … Continue reading CIRM brings together experts in the 6th annual Alpha Clinics Network Symposium at UC Irvine